Who founded Belhaven Biopharma?

Belhaven Biopharma was founded by Scott Lyman, Dave Neal in 2020.

How much funding has Belhaven Biopharma raised?

Belhaven Biopharma has disclosed $32.3M raised across 1 of its 3 known rounds.

Where is Belhaven Biopharma headquartered?

Belhaven Biopharma is headquartered in Chapel Hill, US.

Belhaven Biopharma

Chapel Hill, US · Founded 2020 · Delaware corporation

Find your way into Belhaven Biopharma

465 people in our graph share verified history with the Belhaven Biopharma team — schools, employers, funds. One of them is your warm intro.

Craig Hardingunlockedknows Dave Neal · together at Duke Capital Partners (overlapped)

×11knows the team · via Duke Capital Partners

Belhaven Bio develops a temperature-stable, needle-free delivery device for epinephrine and other emergency medications, designed to be more compact, affordable, and longer-lasting than traditional liquid injectables for patients with severe allergies and anaphylaxis conditions.

Biotech Healthtech Medical Devices

Founders & leadership

Belhaven Biopharma was founded in 2020 by Scott Lyman and Dave Neal.

Scott Lyman CEO and Co-Founder, Chairman of the BoardScott Lyman is CEO and co-founder of Belhaven Biopharma, which develops a temperature-stable, needle-free delivery device for epinephrine and emergency medications. His background includes expertise in business development, corporate finance, and R&D outsourcing.

Dave Neal CFO and Co-Founder, Board MemberDave Neal has over 30 years of experience in venture capital and early-stage financing, serving as a Venture Partner at Duke Capital Partners and as CFO at Belhaven Biopharma. He is also a Professor of the Practice of Entrepreneurship at UNC Kenan-Flagler Business School.

Board

Wes WheelerBoard director

Derek WinstanlyBoard director

Funding

SEC filings, press & company announcements

$32.3M disclosed across 1 of 3 rounds · 2025

Undisclosed amountSeed RoundJan 2025
Source ↗

▶$32.3MraisedOct 2025 · 222 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Wes WheelerDirector
David Algon NealExecutive Officer, Director
Derek WinstanlyDirector
Scott David LymanExecutive Officer, Director

Offering amount: $32.3M
Amount sold: $32.3M
First sale: Aug 2025
Incorporated: Corporation, Delaware, 2020
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Biohaven16 shared keywordsBiohaven is a pharmaceutical company that discovers, develops, and commercializes medications for neurological and neuropsychiatric diseases, including epilepsy, pain, mood disorders, OCD, spinocerebellar ataxia, and spinal muscular atrophy. The company operates as a modern publicly traded entity and was acquired by Pfizer in May 2022 for approximately $13 billion.

Companies competing with Belhaven Biopharma for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Belhaven Biopharma do?: Belhaven Bio develops a temperature-stable, needle-free delivery device for epinephrine and other emergency medications, designed to be more compact, affordable, and longer-lasting than traditional liquid injectables for patients with severe allergies and anaphylaxis conditions.
Who founded Belhaven Biopharma?: Belhaven Biopharma was founded by Scott Lyman, Dave Neal in 2020.
How much funding has Belhaven Biopharma raised?: Belhaven Biopharma has disclosed $32.3M raised across 1 of its 3 known rounds.
Where is Belhaven Biopharma headquartered?: Belhaven Biopharma is headquartered in Chapel Hill, US.